NCT03607513View on ClinicalTrials.gov

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-64264681 in Healthy Male and Female Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

105

Participants

Timeline

Start Date

July 31, 2018

Primary Completion Date

August 9, 2019

Study Completion Date

August 9, 2019

Conditions

Healthy

Interventions

DRUG

JNJ-64264681

For all cohorts except the solid dose formulation cohort, JNJ-64264681 wlll be administered as oral solution. For the solid dose formulation cohort, JNJ-64264681 will be provided as capsules for oral administration.

DRUG

Placebo

Matching placebo to JNJ-64264681 will be administered as oral solution.

Trial Locations (1)

2170

Clinical Pharmacology Unit, Merksem

All Listed Sponsors

lead

Janssen Research & Development, LLC

INDUSTRY

NCT03607513 - A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-64264681 in Healthy Male and Female Participants | Biotech Hunter | Biotech Hunter